Scholars Central

Research articlePublished 2016

Using Human Cancer Cell Lines as In vitro Model for Testing the Efficacy of CDBPA; a New Anticancer Drug

Authors: Fuad Fares, Claus L. Jensen, Stig Larsen, Naiel Azzam, Basem Fares, Steen Lindkær-Jensen

Journal of Tissue Science and Engineering

Volume 7 · Issue 2 · Pages 1–6

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The aim of the present study was to test the efficacy of cis-coordinated complexes of platinum (II) with the polymer of benzene-poly-carboxylic acids derived from lignin (CDBPA) (laboratory code BP-C1), an innovative anticancer compound, on the growth of several solid human cancer cell lines: bladder cancer, chondrosarcoma, colonic cancer, head and neck cancer, hepatic cancer, ovary cancer, pancreatic cancer and prostatic cancer. Furthermore, the effect of CDBPA on non-Hodgkin lymphoma cell lines was also tested. The effect of CDBPA on cell viability was detected by XTT assay and toxicity was detected by measuring the leakage of Lactate dehydrogenase from the cells to the media. The present study has demonstrated that CDBPA is not toxic and able to reduce cell viability substantially and significantly in various human cancer cell lines. When comparison of viability in percentage of the controls at the maximum given dose of CDBPA for each type of cancer cell line, it was found that the largest impact on the viability was on sarcoma, and then decreases via breast, prostatic, head and neck-, pancreatic, colonic cancer and finally ovarian cancer. In addition, the effect of CDBPA on non-Hodgkin lymphoma cell lines was similar to that found in sarcoma cells. We conclude that the effect of CDBPA on cell viability is different and may be dependent on genotype of the cancer cell type. This may indicate different mechanisms of action in the different cancer types. The results obtained from the in vitro studies are important for designing future in vivo studies using animal models and to predict the clinical outcome in human cancer.

Subjects

Engineering

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Tissue Science and Engineering
  • SubjectEngineering
  • BylineArticles whose byline prints “Fuad Fares”
  • BylineArticles whose byline prints “Claus L. Jensen”
  • BylineArticles whose byline prints “Stig Larsen”
  • BylineArticles whose byline prints “Naiel Azzam”
  • BylineArticles whose byline prints “Basem Fares”
  • BylineArticles whose byline prints “Steen Lindkær-Jensen”